Impact of systemic histamine deficiency on the crosstalk between mammary adenocarcinoma and T cells

Journal of Pharmacological Sciences

Volumn 105, Issue 1, 2007, Pages 66-73

  Hegyesi, Hargita ^a   Colombo, Lucas ^b   Pállinger, Éva ^a   Tóth, Sára ^a   Boer, Katalin ^a   Molnár, Viktor ^a   Falus, András ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b Instituto de Oncologia Angel H Roffo   (Argentina)

Author keywords

Cytokine; Histamine; Histidine decarboxylase knock out (HDC KO); Regulatory T cell

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HISTAMINE; HISTIDINE DECARBOXYLASE; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; IMMUNOLOGICAL TOLERANCE; KNOCKOUT MOUSE; LYMPHOCYTE; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TUMOR GROWTH;

EID: 34648822053     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0070636     Document Type: Article

References (39)

1. Packard KA, Khan MM. Effects of histamine on Th1/Th2 cytokine balance. Int Immunopharmacol. 2003;3:909-920.
2. Jutel M. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature. 2001;413:420-425.
3. Falus A. Histamine: Biology and medical aspects. Budapest: SprigMed Publishing Ltd.; 2004.
4. Elenkov IJ, Chrousos GP, Wilder RL. Neuroendocrine regulation of IL-12 and TNF-alpha/IL-10 balance. Clinical Ann N Y Acad Sci. 2000;917:94-105.
5. Idzko M, La Sala A, Ferrari D, Panther E, Herouy Y, Dichmann S, et al. Expression and function of histamine receptors in human monocyte-derived dendritic cells. J Allergy Clin Immunol. 2002;109:839-846.
6. Sonobe Y , Nakane H , Watanabe T, Nakano K. Regulation of Con A-dependent cytokine production from CD4+ and CD8+ T lymphocytes by autosecretion of histamine. Inflamm Res. 2004;53:87-92.
7. Gerloni M, Zanetti M. CD4 T cells in tumor immunity. Springer Semin Immunopathol. 2005;27:37-48.
8. Reome JB, Hylind JC, Dutton RW, Dobrzanski MJ. Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer. Clin Immunol. 2004;111:69-81.
9. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380-384.
10. Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz de Cerio A, Melero I, et al. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol. 2003;171:5931-5939.
11. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999;163:5211-5218.
12. + T cells in tumors from patients with early stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61:4766-4772.
13. + regulatory T cells. Nat Immunol. 2003;4:330-336.
14. Falus A, Hegyesi H, Lázár-Molnár E, Pós Z, László V, Darvas Zs. Paracrine and autocrine interactions in melanoma: histamine is a relevant player in local regulation. Trends Immunol. 2001;22:648-652.
15. Rhodes JM, Campbell BJ. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med. 2002;8:10-16.
16. Plaut M, Lichtenstein LM. Histamine and immune responses. In: Ganellin CR, Parsons ME, editors. Pharmacology of histamine receptors. Bristol: Wright PSG; 1982. p. 392.
17. Khan MM, Keaney KM, Melmon KL. Histamine regulates the generation of human cytolytic T lymphocytes. Cell Immunol. 1989;121:60-73.
18. Hellstrand K, Asea A, Dahlgren C, Hermodsson S. Histaminergic regulation of NK cells: role of monocyte-derived reactive oxygen metabolites. J Immunol. 1994;153:4940.
19. Dohlsten M, Sjogren HO, Carlsson R. Histamine acts directly on human T cells to inhibit interleukin-2 and interferon-gamma production. Cell Immunol. 1987;109:65.
20. Ohtsu H, Tanaka S, Terui T, Hori Y, Makabe-Kobayashi Y, Pejler G, et al. Mice lacking histidine decarboxylase exhibit abnormal mast cells. FEBS Lett. 2001;502:53-56.
21. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000;100:655-669.
22. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nature Immunol. 2003;4:330-336.
23. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107-1111.
24. Tanaka S, Ichikawa A. Recent advances in molecular pharmacology of the histamine systems: immune regulatory roles of histamine produced by leukocytes. J Pharmacol Sci. 2006;101:19-23.
25. Elenkov IJ, Webster E, Papanicolaou, DA. Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J Immunol. 1998;161:2586-2593.
26. Takahashi KH, Yoshida A, Iwagaki H. Histamine regulation of interleukin-18-initiating cytokine cascade is associated with down-regulation of intercellular adhesion molecule-1 expression in human peripheral blood mononuclear cells. J Pharmacol Exp Ther. 2002;300:227.
27. Moore KW, De Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765.
28. Berman RM, Suzuki T, Tahara H, Robbins PD, Narula SK, Lotze M. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol. 1996;157:231-238.
29. Jelinek I, Laszlo V, Buzas E, Pallinger E, Hangya B, Horvath Z, et al. Increased antigen presentation and T(h)1 polarization in genetically histamine-free mice. Int Immunol. 2007;19:51-58.
30. Fallon PG, Jolin HE, Smith P, Emson CL, Townsend MJ, Fallon R, et al. IL-4 induces characteristic Th2 responses even in the combined absence of IL-5, IL-9, and IL-13. Immunity. 2002;17:7-17.
31. Kawakami K, Husain SR, Bright RK, Puri RK. Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts. Cancer Gene Ther. 2001;8:861-868.
32. Tomita K, Okabe S. Exogenous histamine stimulates colorectal cancer implant growth via immunosuppression in mice. J Pharmacol Sci. 2005;97:116-123.
33. Idzko M, La Sala A, Ferrari D, Panther E, Herouy Y, Dichmann S. Expression and function of histamine receptors in human monocyte-derived dendritic cells. J Allergy Clin Immunol. 2002;109:839-846.
34. Caron G, Delneste Y, Roelandts E, Duez C, Bonnefoy JY, Pestel J. Histamine polarizes human dendritic cells into Th2 cell-promoting effector dendritic cells. J Immunol. 2001;167:3682-3686.
35. Van Der Pouw Kraan TC, Snijders A, Boeije LC, De Groot ER, Alewijnse AE, Leurs R. Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J Clin Invest. 1998;102:1866-1873.
36. Itoh H, Takahashi HK, Iwagaki H, Yoshino T, Morimoto Y, Saito S, et al. Effect of histamine on intercellular adhesion molecule-1 expression and production of interferon-[gamma] and interleukin-12 in mixed lymphocyte reaction stimulated with interleukin-18. Transplantation. 2002;74:864-870.
37. Agarwala SS, Sabbagh MH. Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment. Expert Opinion Biol Ther. 2001;1:869-879.
38. Nakamura S, Otani T, Ijiri Y, Motoda R, Kurimoto M, Orita K. IFN-γ-dependent and -independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12. J Immunol. 2000;164:3330-3336.
39. Katsuno G, Takahashi HK, Iwagaki H, Mizuno K, Mori S, Yoshino T, et al. Nafamostat mesilate induces production of interleukin-12 and -18 in human peripheral blood mononuclear cells. J Pharmacol Sci. 2005;98:463-466.